Mark A Strom1, Jonathan I Silverberg2. 1. Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, IL. 2. Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, IL; Department of Preventive Medicine and Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago, IL; Northwestern Medicine Multidisciplinary Eczema Center, Chicago, IL. Electronic address: JonathanISilverberg@Gmail.com.
Abstract
OBJECTIVE: To determine if eczema is associated with an increased risk of a speech disorder. STUDY DESIGN: We analyzed data on 354,416 children and adolescents from 19 US population-based cohorts: the 2003-2004 and 2007-2008 National Survey of Children's Health and 1997-2013 National Health Interview Survey, each prospective, questionnaire-based cohorts. RESULTS: In multivariate survey logistic regression models adjusting for sociodemographics and comorbid allergic disease, eczema was significantly associated with higher odds of speech disorder in 12 of 19 cohorts (P < .05). The pooled prevalence of speech disorder in children with eczema was 4.7% (95% CI 4.5%-5.0%) compared with 2.2% (95% CI 2.2%-2.3%) in children without eczema. In pooled multivariate analysis, eczema was associated with increased odds of speech disorder (aOR [95% CI] 1.81 [1.57-2.05], P < .001). In a single study assessing eczema severity, mild (1.36 [1.02-1.81], P = .03) and severe eczema (3.56 [1.70-7.48], P < .001) were associated with higher odds of speech disorder. History of eczema was associated with moderate (2.35 [1.34-4.10], P = .003) and severe (2.28 [1.11-4.72], P = .03) speech disorder. Finally, significant interactions were found, such that children with both eczema and attention deficit disorder with or without hyperactivity or sleep disturbance had vastly increased risk of speech disorders than either by itself. CONCLUSIONS: Pediatric eczema may be associated with increased risk of speech disorder. Further, prospective studies are needed to characterize the exact nature of this association.
OBJECTIVE: To determine if eczema is associated with an increased risk of a speech disorder. STUDY DESIGN: We analyzed data on 354,416 children and adolescents from 19 US population-based cohorts: the 2003-2004 and 2007-2008 National Survey of Children's Health and 1997-2013 National Health Interview Survey, each prospective, questionnaire-based cohorts. RESULTS: In multivariate survey logistic regression models adjusting for sociodemographics and comorbid allergic disease, eczema was significantly associated with higher odds of speech disorder in 12 of 19 cohorts (P < .05). The pooled prevalence of speech disorder in children with eczema was 4.7% (95% CI 4.5%-5.0%) compared with 2.2% (95% CI 2.2%-2.3%) in children without eczema. In pooled multivariate analysis, eczema was associated with increased odds of speech disorder (aOR [95% CI] 1.81 [1.57-2.05], P < .001). In a single study assessing eczema severity, mild (1.36 [1.02-1.81], P = .03) and severe eczema (3.56 [1.70-7.48], P < .001) were associated with higher odds of speech disorder. History of eczema was associated with moderate (2.35 [1.34-4.10], P = .003) and severe (2.28 [1.11-4.72], P = .03) speech disorder. Finally, significant interactions were found, such that children with both eczema and attention deficit disorder with or without hyperactivity or sleep disturbance had vastly increased risk of speech disorders than either by itself. CONCLUSIONS:Pediatric eczema may be associated with increased risk of speech disorder. Further, prospective studies are needed to characterize the exact nature of this association.
Authors: H Williams; C Robertson; A Stewart; N Aït-Khaled; G Anabwani; R Anderson; I Asher; R Beasley; B Björkstén; M Burr; T Clayton; J Crane; P Ellwood; U Keil; C Lai; J Mallol; F Martinez; E Mitchell; S Montefort; N Pearce; J Shah; B Sibbald; D Strachan; E von Mutius; S K Weiland Journal: J Allergy Clin Immunol Date: 1999-01 Impact factor: 10.793
Authors: Ginette Dionne; Evelyne Touchette; Nadine Forget-Dubois; Dominique Petit; Richard E Tremblay; Jacques Y Montplaisir; Michel Boivin Journal: Sleep Date: 2011-08-01 Impact factor: 5.849
Authors: Jonathan I Silverberg; Lauren Becker; Mary Kwasny; Alan Menter; Kelly M Cordoro; Amy S Paller Journal: JAMA Dermatol Date: 2015-02 Impact factor: 10.282
Authors: Danny Camfferman; J Declan Kennedy; Michael Gold; Carol Simpson; Kurt Lushington Journal: Int J Psychophysiol Date: 2013-01-23 Impact factor: 2.997
Authors: Evelyne Touchette; Dominique Petit; Jean R Séguin; Michel Boivin; Richard E Tremblay; Jacques Y Montplaisir Journal: Sleep Date: 2007-09 Impact factor: 5.849
Authors: Dillon G Pruett; Douglas M Shaw; Hung-Hsin Chen; Lauren E Petty; Hannah G Polikowsky; Shelly Jo Kraft; Robin M Jones; Jennifer E Below Journal: J Fluency Disord Date: 2021-04-15 Impact factor: 2.538
Authors: Vladeta Ajdacic-Gross; Laura Bechtiger; Stephanie Rodgers; Mario Müller; Wolfram Kawohl; Roland von Känel; Margot Mutsch; Wulf Rössler; Erich Seifritz; Enrique Castelao; Marie-Pierre F Strippoli; Caroline Vandeleur; Martin Preisig; Peter Howell Journal: PLoS One Date: 2018-08-07 Impact factor: 3.240